Alatrash, Gheath <br/><br/>
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.  [electronic resource] 

 -  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation  Oct 2011 
 - 1490-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1523-6536 
<br/><br/><label>Standard No.: </label>10.1016/j.bbmt.2011.02.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Disease<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Busulfan--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Follow-Up Studies<br/>Graft vs Host Disease--mortality<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Leukemia, Myeloid, Acute--mortality<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--mortality<br/>Prospective Studies<br/>Survival Rate<br/>Transplantation Conditioning<br/>Transplantation, Homologous<br/>Vidarabine--administration & dosage